newsfilter
← Latest News
Business Wire·

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 Cash, cash equivalents, and marketable securities of $180.8